© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A national survey found that primary care physicians had little interest in prescribing buprenorphine or naltrexone.
A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.
Researchers found critical gaps in the scientific knowledge about the opioid epidemic.
A literature review shows promising signs that teenagers, like adults, can benefit from methadone, buprenorphine and naltrexone.
Researchers followed people with a drug-injection history who had been cured of hepatitis C and were receiving addiction treatment.
A study in Russia found the implant was associated with a higher rate of viral suppression compared with oral naltrexone.
Monthly injections of extended-release naltrexone helps heavy drinkers with HIV cut back.
A group of experts has issued a call to arms, spotlighting missed opportunities for addiction treatment in hospital settings.
A recent study provided extended-release naltrexone along with counseling to HIV-positive individuals.
This long-acting drug is linked to undetectable viral loads in former prisoners with substance use disorders.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
Monthly injections of extended-release naltrexone is linked to viral suppression among this population.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
